TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial

John Nemunaitis,Zsolt Papai,Hervé Léna,Gyorgy Losonczy,Frederic Forget,Christos Chouaid, Alexandra Szczesna,Radj Gervais,Christian H Ottensmeier,Joseph Beck,Andrzej Kazarnowicz,Virginie Westeel,Didier Debieuvre,Anne Madroszyk,Enriqueta Felip, Jean Marc Limacher, Elisabeth Quoix

Journal for ImmunoTherapy of Cancer（2015）

引用 0|浏览20

暂无评分

摘要

Meeting abstracts TG4010 is an immunotherapy using an attenuated and modified poxvirus (MVA) coding for MUC1 and interleukin-2 to induce a cellular immune response against MUC1 expressing tumors. Previous Phase 2 trials have demonstrated the efficacy and safety of TG4010 in combination with

查看译文

关键词

Small Cell Lung Cancer, Time Trial, Immune Checkpoint, Injection Site Reaction, Checkpoint Inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要